CHA
BMY.RT

Carmichael Hill & Associates’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Carmichael Hill & Associates’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-724
Closed – – 792
2020
Q4 		$0 Hold
724
– – ﹤0.01% 769
2020
Q3 		$2K Hold
724
– – ﹤0.01% 674
2020
Q2 		$3K Hold
724
– – ﹤0.01% 623
2020
Q1 		$3K Hold
724
– – ﹤0.01% 597
2019
Q4 		$2K Buy
+724
New +$1.88K ﹤0.01% 656

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Carmichael Hill & Associates's BMY.RT Position: Q1 2021 in Review

Carmichael Hill & Associates sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 724 shares.

Carmichael Hill & Associates first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $3K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Carmichael Hill & Associates reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Carmichael Hill & Associates sold 724 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
  • Carmichael Hill & Associates first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Carmichael Hill & Associates's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $3K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Carmichael Hill & Associates's 13F filing for Q1 2021, filed 28 Apr 2021.